Complex mutations in non-small cell lung cancer: a distinct entity?
作者信息
Bieńkowski Michał, Dziadziuszko Rafał, Jassem Jacek
机构信息
Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland.
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.
出版信息
J Thorac Dis. 2022 Aug;14(8):2738-2741. doi: 10.21037/jtd-2022-05.
Abstract
摘要
相似文献
1
Complex mutations in non-small cell lung cancer: a distinct entity?非小细胞肺癌中的复杂突变：一种独特的实体？
J Thorac Dis. 2022 Aug;14(8):2738-2741. doi: 10.21037/jtd-2022-05.
2
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.中国非小细胞肺癌中靶向下一代测序鉴定的驱动基因的基因组特征。
Oncologist. 2019 Nov;24(11):e1070-e1081. doi: 10.1634/theoncologist.2018-0572. Epub 2019 Mar 22.
3
Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation.吸烟状况与携带罕见表皮生长因子受体突变的非小细胞肺癌患者的关联。
Front Immunol. 2022 Oct 20;13:1011092. doi: 10.3389/fimmu.2022.1011092. eCollection 2022.
4
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.中国非小细胞肺癌患者中表皮生长因子受体的罕见突变类型及对表皮生长因子受体酪氨酸激酶抑制剂的反应
Cancer Chemother Pharmacol. 2017 Dec;80(6):1179-1187. doi: 10.1007/s00280-017-3464-9. Epub 2017 Oct 24.
5
Current management of uncommon EGFR mutations in non-small cell lung cancer.非小细胞肺癌中罕见 EGFR 突变的当前治疗方法。
Curr Probl Cancer. 2024 Apr;49:101064. doi: 10.1016/j.currproblcancer.2024.101064. Epub 2024 Feb 3.
6
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.不同类型 EGFR 突变的晚期非小细胞肺癌患者接受一线酪氨酸激酶抑制剂治疗的临床结局：脑转移和新出现的 T790M 很重要。
BMC Cancer. 2022 Feb 21;22(1):198. doi: 10.1186/s12885-022-09245-5.
7
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.台湾非小细胞肺癌中表皮生长因子受体突变频率高且模式复杂，与吉非替尼反应性相关
Clin Cancer Res. 2004 Dec 15;10(24):8195-203. doi: 10.1158/1078-0432.CCR-04-1245.
8
Genetic predictors of MEK dependence in non-small cell lung cancer.非小细胞肺癌中MEK依赖性的遗传预测因子。
Cancer Res. 2008 Nov 15;68(22):9375-83. doi: 10.1158/0008-5472.CAN-08-2223.
9
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.阿法替尼治疗携带非典型 EGFR 突变的晚期非小细胞肺癌患者的临床活性：LUX-Lung 2、LUX-Lung 3 和 LUX-Lung 6 的联合事后分析。
Lancet Oncol. 2015 Jul;16(7):830-8. doi: 10.1016/S1470-2045(15)00026-1. Epub 2015 Jun 4.
10
Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.表皮生长因子受体酪氨酸激酶抑制剂对携带不同类型表皮生长因子受体突变的非小细胞肺癌患者的疗效：一项回顾性分析。
J Huazhong Univ Sci Technolog Med Sci. 2017 Dec;37(6):864-872. doi: 10.1007/s11596-017-1819-4. Epub 2017 Dec 21.
本文引用的文献
1
Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex mutations: a real-world study.达可替尼在携带复杂突变的非小细胞肺癌患者中的疗效：一项真实世界研究。
J Thorac Dis. 2022 May;14(5):1428-1440. doi: 10.21037/jtd-21-1841.
2
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).德国国家网络基因组医学肺癌（nNGM）中不典型 EGFR 突变的治疗结果。
Ann Oncol. 2022 Jun;33(6):602-615. doi: 10.1016/j.annonc.2022.02.225. Epub 2022 Mar 6.
3
Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis.全球非小细胞肺癌中表皮生长因子受体突变的流行率：一项荟萃分析。
Mol Diagn Ther. 2022 Jan;26(1):7-18. doi: 10.1007/s40291-021-00563-1. Epub 2021 Nov 23.
4
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.对第三代表皮生长因子受体酪氨酸激酶抑制剂的获得性耐药以及新一代表皮生长因子受体抑制剂的出现。
Innovation (Camb). 2021 Apr 3;2(2):100103. doi: 10.1016/j.xinn.2021.100103. eCollection 2021 May 28.
5
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.新型 EGFR 酪氨酸激酶抑制剂在非罕见、非 20 外显子插入 EGFR 突变的 NSCLC 治疗中的作用的最新进展。
J Thorac Oncol. 2021 May;16(5):764-773. doi: 10.1016/j.jtho.2020.12.002. Epub 2020 Dec 14.
6
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation.阿法替尼在携带复杂表皮生长因子受体突变的肺腺癌患者中的疗效。
Ther Adv Med Oncol. 2020 Aug 10;12:1758835920946156. doi: 10.1177/1758835920946156. eCollection 2020.
7
Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma.非小细胞肺癌中与不同致病性突变相关的四代 EGFR TKI。
J Drug Target. 2020 Nov;28(9):861-872. doi: 10.1080/1061186X.2020.1737934. Epub 2020 Mar 12.
8
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal.表皮生长因子受体非常见突变在非小细胞肺癌中的意义：系统评价和批判性评估。
Cancer Treat Rev. 2020 Apr;85:101994. doi: 10.1016/j.ctrv.2020.101994. Epub 2020 Feb 21.
9
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.阿法替尼治疗具有罕见表皮生长因子受体（EGFR）突变的非小细胞肺癌：一个包含693例病例的数据库。
J Thorac Oncol. 2020 May;15(5):803-815. doi: 10.1016/j.jtho.2019.12.126. Epub 2020 Jan 10.
10
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
Zotero 插件